Abolis Biotechnologies, a trailblazer in sustainable biotechnology, has recently secured €35 million in funding, a milestone achievement for the French startup. This significant investment round was led by an international consortium of investors, including BOLD, L’Oréal’s venture capital arm.
Strategic Funding for Future Growth
In a significant move, Abolis Biotechnologies has successfully secured €35 million in funding, marking a pivotal step for the French startup. The funding round was driven by a diverse consortium of international investors. These include BOLD, L’Oréal’s venture capital wing, alongside Evonik Venture Capital and impact-focused funds like Germany’s DeepTech & Climate Fonds, Singapore’s Clay Capital, Netherlands’ ICOS Capital, and the transatlantic investment firm Liberset.
Utilisation of Funds
The investment aims to turbocharge Abolis’ expansion into global markets and step up its research and development efforts. The company plans to introduce innovative biomanufacturing and microbiome solutions, leveraging this capital influx. This will allow Abolis to scale its operations significantly, accelerating business development and creating its own line of products. Moreover, the activities of its Microbiome Studio—a business unit focused on decrypting and engineering microbial ecosystems—will see considerable growth.
Abolis Biotechnologies: A Pioneer in Sustainability
Founded in 2014 by Cyrille Pauthenier and Valerie Brunel, Abolis Biotechnologies champions high-impact innovations in biotechnology. By offering customised industrial solutions based on natural and modified microorganisms, Abolis supports industries aiming for sustainable production models. The alternatives presented by the company are economically viable and environmentally friendly, reducing reliance on petrochemicals and plant extracts. As Cyrille Pauthenier, CEO of Abolis Biotechnologies, noted, “This strategic funding will fuel our continued growth trajectory, strengthening our position as a European leader in biomanufacturing and microbiome solutions.”
Investors’ Perspectives and Strategic Collaborations
L’Oréal, through its venture capital arm BOLD, has reinforced its ongoing collaboration with Abolis, a partnership that commenced in 2019. Samantha Etienne, CEO of BOLD, stated, “We are looking forward to collaborating with the talented Abolis team to support their continued growth and success.” Similarly, Bernhard Mohr from Evonik Venture Capital, highlighted their shared vision with Abolis, emphasizing their compatibility in strain development and metabolic engineering. Such alliances are expected to open doors to markets in cosmetics, nutrition, and healthcare.
A Broader Industrial Commitment to Biotechnology
The move by Abolis is seen as a catalytic moment for biotechnology’s role in sustainable transformation across industries. DeepTech & Climate Fonds highlighted this with Tobias Faupel noting, “Our investment in Abolis marks an important milestone — it’s not only our first step into biotechnology but also our first venture outside of Germany.” With commitments from cosmetic, pharmaceutical, and agricultural industries to shift to bio-based ingredients, Abolis stands at a crucial juncture in facilitating this transition.
Impact and Future Prospects
Abolis’ innovative approach delivers significant traction with key industry players, making strides in biobased ingredient development. Collaborations and partnerships enable Abolis to extend its reach across Europe and into Asia, where demand for sustainable solutions is strong. Peter van Gelderen from Icos Capital stressed the strategic importance of this growth financing round, aiming to position Abolis as a market leader in green ingredients.
Concluding Remarks
This latest funding round cements Abolis’ status as a leader in the European industrial biotechnology sector. Liberset’s Damien Bourel praised the investment as a step towards a greener future, underscoring the strategic partnership’s potential in expanding across the Atlantic.
Abolis Biotechnologies has positioned itself at the forefront of sustainable biotechnological innovation through strategic partnerships and substantial investment. The €35 million funding not only signifies a vote of confidence from major industry players but also sets the stage for Abolis to enhance its contributions to sustainable industrial solutions.
